Transplantation of DBA/2 Mouse Corneas in BALB/c Recipients Significantly Delays Graft Rejection Compared with C3H Grafts and Facilitates Studies on Gene Transfer

R. Ignatius1,*, E.-P. Zhang2, F. Schulte2, M. Schroff3, U. Rüschendorf1, A. Müller2, B. Wittig3,4 and F. Hoffmann2

1Institute of Microbiology and Hygiene, Department of Infection Immunology, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 27, 12203 Berlin; 2Department of Ophthalmology, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin; 3Mologen AG, 14180 Berlin, Germany and 4Charité, Department of Molecular Biology and Bioinformatics, Arnimallee 22, 14195 Berlin Germany

Abstract: To study the impact of gene transfer in experimental corneal transplantation, grafts should reliably be rejected but after a time span, which allows multiple interventions. We were interested in delaying transplant survival time through MHC-matching of donor and recipient animals and in omitting local dexamethasone treatment, which is laborious and could potentially interfere with the expression of administered DNA. Rejection of DBA/2 (H-2d) corneas by BALB/c (H-2d) recipients occurred significantly delayed compared with C3H (H-2k) grafts (25.0 ± 5.6 vs. 14.5 ± 4.1 days, p=0.038), and correlated with the expression of allospecific T cell-proliferation and IFN-γ secretion in draining lymph nodes. Gene gun treatment with IL-4/CTLA-4 DNA MIDGE™ vectors in the lower lid of recipients significantly prolonged survival of DBA/2 corneas in BALB/c mice. This refined and dexamethasone-free protocol may be advantageous for the development of novel treatment strategies, e.g., local gene transfer, in corneal transplantation.

INTRODUCTION

Gene therapy holds great promise for various corneal disorders including allograft rejection. Three different technical approaches have been shown to be feasible, i.e., treatment of the corneal epithelium, the stroma, or the endothelium. While both stroma and endothelium can be manipulated only before or during the procedure of transplantation, repeated treatments of the epithelium are feasible following keratoplasty. We previously showed prolonged survival of murine corneal grafts following transfer of cytokine DNA by gene gun treatment to the cornea [1] and also to the lower lid [2]. Regarding the way of gene delivery we opted for small gene vectors in order to keep vector-induced inflammatory reactions to a minimum.

One standard mouse model for studying corneal allograft survival has been established by embedding grafts from C57Bl/6 mice into the eyes of BALB/c recipients [3]. While this model allows studies aimed at understanding the immunological mechanisms underlying graft rejection, it is not optimal for studying the impact of gene therapy on the process of rejection, since – although MHC-mismatched mouse strains are used – less than 50% of the grafts are rejected. A mouse model with a rejection rate of 100%, however, is required for a comprehensive evaluation of strategies that intend to prolong survival or interfere with rejection. In our previous experimental model (C3H-donors and BALBc-recipients) acute rejection of the grafts generally occurs within around two weeks in 100% of the recipients [4]. To prolong the time between transplantation and rejection, treatment with dexamethasone eye drops is mandatory. However, multiple daily applications of eye drops to mice are laborious and corticosteroids could potentially interfere with the expression of peri-operatively administered cytokine DNA.

Although minor histocompatibility antigens may be more important for corneal graft rejection than MHC molecules [5, 6], we tested whether the use of MHC-identical mouse strains, which only display different minor histocompatibility antigens, may provide an experimental model that is better suited for gene transfer strategies. Here we show that the use of DBA/2 donor and BALB/c recipient mice further delays graft rejection and thereby provides additional time that can be used to interfere with the induction of allospecific immune responses.

MATERIALS AND METHODS

Animals

Three-month-old female mice weighing 20 to 25 g were obtained from the Bomholtgard Breeding and Research Center (Denmark). Corneal grafts from 3 C3H (H-2k) or 15 DBA/2 (H-2d) mice were transplanted in 36 BALB/c (H-2d) mice. All animals were treated according to the "Principles of Laboratory Animal Care" (NIH publication Vol. 25, No. 28, revised in 1996). Two additional C3H and 2 DBA/2 mice
were sacrificed without prior treatment and the corneas were removed for immunohistochemical analyses.

Orthotopic Corneal Transplantation and Post-Operative Treatment

As the numbers of APCs per graft could potentially influence the time between transplantation and rejection, sections of the corneal stroma obtained from both mouse strains were analyzed immunohistologically regarding myeloid cells of the macrophage/dendritic cell lineage, which stain positive for F4/80 and MHC class II molecules [7]. Corneas from both mouse strains showed a similar distribution and contained comparable numbers of F4/80+ cells (C3H: 29.8 ± 6.1 cells/section; DBA/2: 20.3 ± 5.1 cells/section; p=0.06).

Procedures of corneal transplantation and anesthesia have previously been described [8, 9]. Two and seven days after transplantation sutures were removed from the lids and corneas, and all animals were examined at the slit-lamp. Subsequently, transparency of corneal grafts was assessed every one to two days as edema and/or clouding and rated on a scale of 0 to 5 points [3], an allograft reaction being diagnosed with >2 points.

Immunohistochemistry

Tangential sections from frozen flattened corneas from 2 untreated C3H and 2 DBA/2 mice were cut from the most superficial subepithelial corneal layer [7], and F4/80+ cells were stained with a rat anti-mouse F4/80 monoclonal antibody (mAb) (Clone Cl:A3-1, Dako, Hamburg, Germany) followed by a biotinylated mouse anti-rat mAb (Pharmingen, Heidelberg, Germany). The reaction was visualised using an avidin-biotin-complex alkaline phosphatase kit (Vectastain®, Alexis Corp., Grünberg, Germany). Data are given as mean numbers of cells per section +/- SD.

Allospecific Immune Responses

Non-specific inflammation can limit corneal transplant survival, and we previously used dexamethasone locally to avoid non-specific inflammatory responses. To ensure that the grafts in the present model in the absence of steroids were rejected due to the expression of T cell-mediated immune responses, we determined the presence of allospecific T lymphocytes in the draining lymphoid tissue.

7.5x10⁶ pooled cells from the ipsilateral or contralateral submandibular lymph nodes of recipient mice were incubated with 7.5x10⁶ irradiated spleen cells in triplicates in RPMI 1640 (GIBCO, Invitrogen, Karlsruhe, Germany), supplemented with 2 mM L-glutamine (GIBCO), 50 μM 2-mercaptoethanol (Sigma, Deisenhofen, Germany), 10 mM HEPES (GIBCO), penicillin (100 U/ml)-streptomycin (100 μg/ml) (GIBCO), and 10% heat-inactivated fetal calf serum (Biochrom, Berlin, Germany) in 96-well round bottom trays (Nunc, Roskilde, Denmark) at 37°C and 5% CO₂. On day 3, supernatants were harvested and stored at −70°C for analysis of interferon (IFN)-γ secretion. As controls, lymph node cells were stimulated by Concanavalin A (Con A, 5 μg/ml, Sigma, Deisenhofen, Germany) or incubated in the presence of medium alone. Tritiated thymidine (1 μCi/well, NEN, Köln, Germany) was added to the wells, and ³H-thymidine incorporation was measured as cpm after another 18 h of incubation. Successful irradiation was confirmed by incubation of spleen cells in the presence of ConA, and proliferation of these cultures never exceeded 2000 cpm. IFN-γ concentrations in cell culture supernatants were determined using a commercially available ELISA (BD Biosciences, San Diego, USA).

Gene Therapy

Minimalistic, immunologically-defined, gene expression (MIDGE™) constructs were provided by Mologen (Berlin, Germany) and were synthesized as described before [1]. Vectors were administered with the Helios Gene Gun® delivery system (Bio-Rad Laboratories, München, Germany) using 1 mg of 1.6-μm gold powder (ABCr, Karlsruhe, Germany) loaded with 1 μg of MIDGE DNA and using a helium pressure setting of 250 psi. Cartridges containing gold particles coated with MIDGE™ constructs were prepared according to the manufacturer’s instructions. The skin of the left lower lids or of the left shanks was treated three times within one minute at the time of transplantation and on days 2 and 7 after keratoplasty (total DNA load: 9 μg).

Statistics

Data were statistically analyzed using the Mann-Whitney U test.

RESULTS

Prolonged Survival of DBA/2 Compared to C3H Grafts in BALB/c Recipients

Two groups of six BALB/c mice each received corneal grafts from either C3H or DBA/2 mice. Despite local antibiotic treatment, two eyes (transplanted with grafts from the same donor animal) got postoperatively infected, and the recipients were excluded from the study. All other grafts were clear when the lids were opened. Allograft rejection occurred on day 14.5 ± 4.1 (mean ± SD) when C3H donors were used and on day 25.0 ± 5.6 with grafts from DBA/2 donors (p=0.038, Fig. 1).

Fig. (1). Use of MHC-matched donor and recipient mouse strains significantly prolongs corneal graft survival. BALB/c mice received corneal grafts from either C3H (dotted line) or DBA/2 mice (bold line). Cumulative survival of allografts is shown (p=0.038).

T-cell proliferative responses were detected one to two days after the onset of rejection in draining lymph nodes following transplantation of C3H or DBA/2 donor corneas.
(Table 1), and these T cells secreted substantial amounts of IFN-\(\gamma\) (Table 2). These Th1 immune responses of BALB/c recipients did not differ considerably after transplantation of C3H or DBA/2 corneas. Thus, transplantation of DBA/2 corneas into BALB/c mice leads to a longer graft survival than transplantation of C3H corneas and graft rejection is due to the expression of allospecific immune responses. Importantly, still all grafts are rejected, which is favourable for studies that intend to interfere with graft rejection.

### Table 1. Alloreactive T-Cell Proliferation in Lymph Node Cells from BALB/c Mice at the Time of Rejection of Corneal Grafts from C3H or DBA/2 Mice

<table>
<thead>
<tr>
<th>Donor Mouse Strain</th>
<th>Site of Lymph Nodes</th>
<th>Stimuli</th>
<th>Spleen Cells*</th>
<th>Medium</th>
<th>ConA</th>
</tr>
</thead>
<tbody>
<tr>
<td>C3H</td>
<td>ipsilateral</td>
<td>31,996</td>
<td>8,540</td>
<td>291,461</td>
<td></td>
</tr>
<tr>
<td></td>
<td>contralateral</td>
<td>8,789</td>
<td>3,696</td>
<td>276,732</td>
<td></td>
</tr>
<tr>
<td>DBA/2</td>
<td>ipsilateral</td>
<td>73,698</td>
<td>7,625</td>
<td>290,304</td>
<td></td>
</tr>
<tr>
<td></td>
<td>contralateral</td>
<td>17,115</td>
<td>8,747</td>
<td>194,279</td>
<td></td>
</tr>
</tbody>
</table>

*Lymph node cells were stimulated by irradiated donor spleen cells, ConA (5 \(\mu\)g/ml) as a positive control, or incubated in the presence of medium alone (negative control). Proliferation was measured as cpm on day 3, results of irradiated spleen cells incubated in the presence of ConA never exceeded 2000 cpm.

### Table 2. IFN-\(\gamma\) Secretion (ng/ml) by Submandibular Lymph Node Cells from BALB/c Mice at the Time of Rejection of Corneal Grafts from C3H or DBA/2 Mice

<table>
<thead>
<tr>
<th>Donor Mouse Strain</th>
<th>Site of Lymph Nodes</th>
<th>Stimuli</th>
<th>Spleen Cells*</th>
<th>Medium</th>
<th>ConA</th>
</tr>
</thead>
<tbody>
<tr>
<td>C3H</td>
<td>ipsilateral</td>
<td>19.10</td>
<td>&lt;0.36</td>
<td>62.26</td>
<td></td>
</tr>
<tr>
<td></td>
<td>contralateral</td>
<td>0.66</td>
<td>&lt;0.36</td>
<td>59.19</td>
<td></td>
</tr>
<tr>
<td>DBA/2</td>
<td>ipsilateral</td>
<td>14.00</td>
<td>&lt;0.36</td>
<td>65.19</td>
<td></td>
</tr>
<tr>
<td></td>
<td>contralateral</td>
<td>&lt;0.36</td>
<td>&lt;0.36</td>
<td>56.34</td>
<td></td>
</tr>
</tbody>
</table>

*Lymph node cells were stimulated by irradiated donor spleen cells, ConA (5 \(\mu\)g/ml) as a positive control, or incubated in the presence of medium alone (negative control). Supernatants were harvested after 3 days.

**Successful Gene Therapy Further Extends Survival Time of DBA/2 Grafts in BALB/c Recipients**

We have previously shown that ballistic gene transfer of CTLA-4 and IL-4 DNA into the lower lid significantly prolongs the survival time of the grafts whereas transfer of empty control vectors did not affect transplant survival [2]. To confirm that the present model still allows experimental gene transfer strategies, we treated two groups of BALB/c recipients of DBA/2 corneas (n=8 each) through ballistic gene transfer of CTLA-4 and IL-4 DNA into the skin of the lower lid or the shank, however, less frequently than in our previous studies. Eight additional recipients remained untreated. Postoperatively, one lid-treated and one untreated animal were excluded because of infection while all other grafts were clear when the lids were opened. Allograft rejection occurred in six of the seven remaining control animals, in seven of the eight shank-treated, and in three of the seven lid-treated animals (Fig. 2). The remaining six grafts (one in the controls, one in the shank-treated, and four in the lid-treated animals) remained clear until day 33 (p=0.026 lid-treated vs. untreated, p=0.040 lid-treated vs. shank-treated). Therefore, grafting of DBA/2 corneas into BALB/c recipients allows gene therapy and provides a longer time span for the performance of therapeutic strategies intending to interfere with graft rejection than our previously established model.

**DISCUSSION**

The present study aimed at establishing a murine model of keratoplasty with – in the absence of local corticosteroid treatment – a delayed (longer than 14 days) but reliable rejection of all grafts to set stage for future studies of gene transfer. Although there is ample evidence that minor histocompatibility antigens play an important role in corneal graft rejection [5, 6] the present study demonstrates that the use of the MHC-matched DBA/2 and BALB/c mouse strains leads to a significantly delayed rejection of the grafts compared with MHC-mismatched C3H donors. Nevertheless, we cannot exclude that the longer survival of the grafts in our model is due to a favorable match regarding minor histocompatibility antigens.

A benefit of MHC-matching in murine corneal transplantation has also been reported by Yamada et al. [10] who demonstrated differences in corneal allograft survival depending on whether they placed MHC-matched and MHC-mismatched grafts in high-risk graft beds. The modulation of the intracellular thiol status of macrophages (and possibly also of other antigen-presenting cells, such as dendritic cells) in BALB/c recipients prior to transplantation led to a pro-
longed survival of MHC-matched but minor histocompatibility antigen incompatible grafts, e.g., B10.D2 and also DBA/2 grafts as in our experiments. In contrast, there was no suppressive effect by the induction of oxidative antigen-presenting cells on the rejection of grafts from MHC-mismatched mouse strains (C57Bl/10 grafts in BALB/c recipients). Likewise, MHC-matching reduces the risk of corneal graft rejection when IFN-γ secretion is depressed or absent [11].

This new model is less laborious and importantly, more adapted to the performance of gene therapy studies than our previous model [1, 2]. Daily dexamethasone eye drops, which could potentially interfere with the expression of the DNA brought in through gene transfer, are dispensable for the achievement of a graft survival time longer than 14 days. In addition, corneal sutures can be removed earlier after surgery than before. The modified experimental protocol allows repeated therapeutic interventions, as shown by the results of our gene transfer experiment – ballistic gene transfer may even be more effective under these conditions –, and future studies in this model may concentrate on influencing the allograft rejection by using genes of various cytokines at several treatment times. In conclusion, the model of transplantation of DBA/2 corneal grafts into BALB/c recipients provides an improved animal model for investigating experimental methods aiming at the prolongation of graft survival, particularly for studies of gene transfer to the cornea or the lower lid.

CONFLICT OF INTEREST

MS and BW are affiliated with MOLOGEN AG, Berlin, Germany, and hold publicly traded shares of the company (ISIN DE0006637200). RI, E-PZ, FS, UR, AM, and FH declare no conflicts of interests.

ACKNOWLEDGEMENT

We thank the Deutsche Forschungsgemeinschaft (Ho 674/9-3 to FH) for financial support.

REFERENCES